Sanofi and Regeneron release results of Phase 3 study on Dupixent

Moderate-to-severe AD is a lifelong chronic inflammatory disease.
Moderate-to-severe AD is a lifelong chronic inflammatory disease. | File photo

Sanofi and Regeneron Pharmaceuticals Inc. recently shared the results of a Phase 3 Chronos study as a late-breaking abstract at the annual meeting of the American Academy of Dermatology.

The study had evaluated Dupixent as a treatment to be used in conjunction with topical corticosteroids for patients with uncontrolled moderate-to-severe atopic dermatitis (AD).

“Moderate-to-severe AD is a lifelong chronic inflammatory disease,” the companies wrote in a press release. “Despite currently available therapies, there still remains an unmet need for treatment to help those adults struggling to manage their moderate to severe AD.”

Dupixent is under priority review by the U.S. Food and Drug Administration.

Sanofi is a global health care company that focuses on therapeutic solutions helping patients lead healthier lives. It has five business units – Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Regeneron, a science-based biopharmaceutical company, develops medicines for serious medical conditions and has product candidates in development in other areas of high unmet medical need.

Want to get notified whenever we write about Sanofi US ?
Next time we write about Sanofi US, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

Sanofi US 55 Corporate Dr Bridgewater, NJ - 08807